Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study
Open Access
- 23 January 2024
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 171, 116177
Abstract
No abstract availableKeywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (214844)
This publication has 29 references indexed in Scilit:
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese SubjectsClinical Therapeutics, 2015
- The impact of leptin on perinatal development and psychopathologyJournal of Chemical Neuroanatomy, 2014
- Effectiveness of gestational diabetes treatment: A systematic review with quality of evidence assessmentDiabetes Research and Clinical Practice, 2012
- The Human Placental Perfusion Model: A Systematic Review and Development of a Model to Predict In Vivo Transfer of Therapeutic DrugsClinical Pharmacology & Therapeutics, 2011
- Hyperglycemia and Adverse Pregnancy OutcomesNew England Journal of Medicine, 2008
- Leptin in Pregnancy: An Update1Biology of Reproduction, 2006
- Directional secretion and transport of leptin and expression of leptin receptor isoforms in human placental BeWo cellsMolecular and Cellular Endocrinology, 2005
- Progesterone and human placental lactogen inhibit leptin secretion on cultured trophoblast cells from human placentas at termGynecological Endocrinology, 2005
- Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships.Diabetes, 2000
- Sodium butyrate stimulates hCG and hCG-? production in a human choriocarcinoma cell line (BeWo)Journal of Cancer Research and Clinical Oncology, 1981